Ekman Lars
Known title: DirectorCIK: 0001376117
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
Transaction History
| PRTA | ▲ Buy | Option Exercise | 15,834 | $101K | 1/3/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 3,411 | $185K | 1/3/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 2,897 | $160K | 1/3/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 6,621 | $373K | 1/3/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 1,303 | $74K | 1/3/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 1,523 | $89K | 1/3/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 10 | $595 | 1/3/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 69 | $4K | 1/3/2023 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 15,834 | $101K | 12/1/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 9,813 | $601K | 12/1/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 6,021 | $374K | 12/1/2022 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 15,833 | $101K | 11/1/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 9,143 | $567K | 11/1/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 1,717 | $108K | 11/1/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 3,312 | $213K | 11/1/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 1,661 | $108K | 11/1/2022 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 15,833 | $101K | 10/3/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 3,508 | $212K | 10/3/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 4,277 | $261K | 10/3/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 6,355 | $395K | 10/3/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 1,693 | $107K | 10/3/2022 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 31,666 | $203K | 9/28/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 31,666 | $1.5M | 9/28/2022 | View on chart |
| RARE | ▲ Buy | Grant | 3,300 | $0 | 6/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Prothena included in Alzheimer's Day stock watchlist
Prothena was featured in a Yahoo Finance article listing four Alzheimer's drug stocks to watch on World Alzheimer's Day. This inclusion highlights the company's relevance in the neurodegenerative disease sector. The stock is currently trading near its 52-week low, with technical indicators showing a rejection at support levels.
Prothena included in Alzheimer's Day stock watchlist. Prothena was featured in a Yahoo Finance article listing four Alzheimer's drug stocks to watch on World Alzheimer's Day. This inclusion highlights the company's relevance in the neurodegenerative disease sector. The stock is currently trading near its 52-week low, with technical indicators showing a rejection at support levels.